Your session is about to expire
← Back to Search
Astegolimab for Chronic Obstructive Pulmonary Disease
Study Summary
This trial will test if adding astegolimab to standard COPD maintenance therapy can reduce exacerbations in patients with a history of them.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 2 trial • 396 Patients • NCT04386616Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I've had 2 or more severe health flare-ups in the last year.I am enrolled or planning to enroll in a lung rehab program.I have been on oxygen therapy using more than 4 liters per minute for a long time.I have had a lung transplant.I've had 2 or more severe health flare-ups in the last year.I often feel short of breath when moving around.I have been on a stable COPD treatment plan for at least 4 weeks.I've had 2 or more severe health flare-ups in the last year.I started taking medication for breathing issues within the last 4 weeks.I have a serious lung condition that is not COPD.I have been diagnosed with COPD for at least a year.I have not had a heart attack or severe heart failure in the last year.You have smoked the equivalent of 10 packs of cigarettes per year for at least one year.I have smoked at least 10 packs of cigarettes a year.Your lung function test shows that your breathing capacity is between 20% and 80% of what is expected for someone your age and size.I have not had lung surgery to reduce volume in the last year.I have smoked at least 10 pack-years.I have been diagnosed with asthma in the last 5 years.I haven't had a severe lung issue or been hospitalized for it in the last 4 weeks.I haven't taken any corticosteroids in the last 4 weeks.
- Group 1: Astegolimab Q2W
- Group 2: Astegolimab Q4W
- Group 3: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does my profile meet the criteria for participation in this experiment?
"This trial aims to admit 930 individuals between the ages of 40 and 90 who suffer from obstructed airflow due to chronic obstructive pulmonary disease (COPD). Additional criteria for participation include: a physician diagnosis, exacerbation history within 24 months prior to screening, post-bronchodilator FEV1 measurement that is above 20% but below 80%, an mMRC score of 2 or greater, smoking status with at least 10 pack years under their belt, and optimized standard-of-care COPD maintenance therapy for four weeks."
Could you provide an overview of the previous investigations conducted on Astegolimab?
"Presently, Astegolimab is being trialed in 1 clinical study. However, none of these trials are at the last stage (Phase 3). With 256 locations globally taking part in this research effort and the majority based out of Tel Aviv-Yafo and Texas."
Does this research accommodate geriatric individuals?
"This medical trial has an age limit of 40 to 90 years old for enrollees. For those below the age requirement, there are 34 studies available and 461 alternative options accessible for individuals beyond the upper threshold."
Are there any current opportunities for enrolment in this medical trial?
"Affirmative. The clinicaltrials.gov website reveals that this medical trial, initially posted on October 5th 2021, is actively enrolling participants. In total, 71 sites are trying to recruit 930 patients for the study."
Is this medical trial a pioneering effort in its field?
"Presently, Astegolimab is the subject of one active study in 25 nations and 80 cities. This investigation, spearheaded by Genentech Inc., first commenced in 2021 with 930 participants and achieved Phase 2 approval status. Since then 18328 studies have been conducted."
How many medical establishments are offering this clinical trial?
"Presently, this medical trial is being conducted out of 71 locations spread throughout the United States. Some prominent sites include Little Rock, Redding and Hannibal. To minimize travel requirements it's recommended to select a clinic close to you if you choose to enroll in the study."
How many individuals are receiving treatment as part of this trial?
"This clinical trial needs 930 applicants who meet the designated criteria to participate. Potential patients can join at Atria Clinical Research - Clinedge - PPDS in Little Rock, Arkansas or Paradigm Clinical Research Institute Inc - ClinEdge-PPDS located in Redding, California."
Has the FDA authorized utilization of Astegolimab for medical procedures?
"The safety profile of astegolimab has been assigned a score of 2, as there is some data in support of its security but no evidence to suggest efficacy."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
How responsive is this trial?
Typically responds via
Share this study with friends
Copy Link
Messenger